Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
The present invention relates to the compound of formula (I): or a salt, preferably a pharmaceutically acceptable salt, thereof; is an inhibitor of spleen tyrosine kinase (SYK) and therefore potentially of use in treating diseases resulting from inappropriate mast cell activation, for instance allergic and inflammatory diseases, as well of potential use in cancer therapy, specifically heme malignancies.
1. A compound of formula (I):
or a salt thereof.
2. A pharmaceutically acceptable salt of a compound of Formula (I) as claimed in claim 1 .
3. A process for preparing a compound of formula (I) or a salt thereof according to claim 1 , which process comprises the steps of:
(i) reacting a compound of formula (II):
with a compound of formula (III):
wherein P is a protecting group; and
(ii) removing P.
4. A pharmaceutical composition comprising a compound of formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
5. A method of treating B lymphoma tumors, which method comprises administering to a patient in need thereof an effective amount of a compound of formula (I) as described in claim 1 or a pharmaceutically acceptable salt thereof.